Program for Inherited Metabolic Diseases, Department of Genetics & Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA.
Mol Genet Metab. 2010 Feb;99(2):116-23. doi: 10.1016/j.ymgme.2009.09.008. Epub 2009 Sep 27.
Combined methylmalonic aciduria and homocystinuria, cobalamin C (cblC) type, is an inherited disorder of vitamin B(12) metabolism caused by mutations in MMACHC. CblC typically presents in the neonatal period with neurological deterioration, failure to thrive, cytopenias, and multisystem pathology including renal and hepatic dysfunction. Rarely, affected individuals present in adulthood with gait ataxia and cognitive decline. Treatment with hydroxocobalamin may ameliorate the clinical features of early-onset disease and prevent clinical late-onset disease. Propionic acidemia (PA), methylmalonic acidemia (MMA), and various disorders of cobalamin metabolism are characterized by elevated propionylcarnitine (C3) on newborn screening (NBS). Distinctions can be made between these disorders with secondary analyte testing. Elevated methionine is already routinely used as a NBS marker for cystathionine beta-synthase deficiency. We propose that low methionine may be useful as a secondary analyte for specific detection of cbl disorders among a larger pool of infants with elevated C3 on NBS.
Retrospective analysis of dried blood spot (DBS) data in patients with molecularly confirmed cblC disease.
Nine out of ten patients with confirmed cblC born in New York between 2005 and 2008 had methionine below 13.4mumol/L on NBS. Elevated C3, elevated C3:C2 ratio, and low methionine were incorporated into a simple screening algorithm that can be used to improve the specificity of newborn screening programs and provide a specific and novel method of distinguishing cblC from other disorders of propionate metabolism prior to recall for confirmatory testing.
It is anticipated that this algorithm will aid in early and specific detection of cobalamin C, D, and F diseases, with no additional expense to NBS laboratories screening for organic acidemias and classical homocystinuria.
甲基丙二酸血症合并同型半胱氨酸血症(cblC 型)是一种遗传性维生素 B12 代谢紊乱疾病,由 MMACHC 基因突变引起。cblC 型通常在新生儿期表现为神经恶化、生长不良、血细胞减少和多系统病理学改变,包括肾功能和肝功能障碍。极少数情况下,受影响的个体在成年期出现步态共济失调和认知能力下降。使用羟钴胺素治疗可能改善早发型疾病的临床特征,并预防临床迟发型疾病。丙酸血症(PA)、甲基丙二酸血症(MMA)和各种钴胺素代谢紊乱的特征是新生儿筛查(NBS)中丙酰肉碱(C3)升高。通过次级分析物检测可以区分这些疾病。高蛋氨酸已常规用于胱硫醚β-合酶缺乏症的 NBS 标志物。我们提出,低蛋氨酸可能作为一种二级分析物,用于在 NBS 中 C3 升高的更大婴儿群体中特异性检测 cbl 疾病。
对经分子证实的 cblC 疾病患者的干血斑(DBS)数据进行回顾性分析。
2005 年至 2008 年期间在纽约出生的 10 例确诊为 cblC 的患者中,有 9 例 NBS 蛋氨酸值低于 13.4umol/L。将升高的 C3、升高的 C3:C2 比值和低蛋氨酸纳入一个简单的筛选算法中,该算法可用于提高新生儿筛查计划的特异性,并在召回进行确认性检测之前提供一种特异性的新方法,用于区分 cblC 与其他丙酸代谢紊乱。
预计该算法将有助于早期和特异性检测钴胺素 C、D 和 F 疾病,而不会增加 NBS 实验室筛查有机酸血症和经典同型胱氨酸尿症的额外费用。